ABCL logo

ABCL
AbCellera Biologics Inc

8,205
Mkt Cap
$1.05B
Volume
5.88M
52W High
$6.52
52W Low
$1.89
PE Ratio
-6.19
ABCL Fundamentals
Price
$3.57
Prev Close
$3.51
Open
$3.51
50D MA
$4.97
Beta
1.35
Avg. Volume
5.75M
EPS (Annual)
-$0.5533
P/B
1.11
Rev/Employee
$48,377.52
Loading...
Loading...
News
all
press releases
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and...
Business Wire·15d ago
News Placeholder
More News
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Posts Quarterly Earnings Results
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·15d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded shares of AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·15d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - What's Next?
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - What's Next...
MarketBeat·17d ago
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -11.76% and +35.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18d ago
News Placeholder
AbCellera Reports Q3 2025 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated...
Business Wire·18d ago
News Placeholder
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +29.41% and +146.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest ABCL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.